Pulmatrix (NASDAQ:PULM – Get Free Report) issued its earnings results on Friday. The biotechnology company reported ($0.54) EPS for the quarter, Zacks reports. Pulmatrix had a negative return on equity of 45.97% and a negative net margin of 96.51%.
Pulmatrix Trading Down 1.7 %
Shares of PULM stock opened at $7.47 on Friday. The firm has a 50-day moving average price of $7.47 and a 200 day moving average price of $5.17. Pulmatrix has a twelve month low of $1.56 and a twelve month high of $10.40. The company has a market capitalization of $27.27 million, a price-to-earnings ratio of -2.83 and a beta of 1.66.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of Pulmatrix in a research report on Sunday, January 5th. They issued a “hold” rating on the stock.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Recommended Stories
- Five stocks we like better than Pulmatrix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Upcoming IPO Stock Lockup Period, Explained
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
- Trading Halts Explained
- MarketBeat Week in Review – 03/17 – 03/21
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
